United States Drug Patent 10,610,125: Scope of Claims, Coverage Boundaries, and AML-Targeted Landscape
What does US 10,610,125 claim in plain scope terms?
US 10,610,125 claims methods of treating acute myelogenous leukemia (AML) where the disease is characterized by a mutant IDH1 or mutant IDH2 enzyme that generates 2-hydroxyglutarate (2HG) via conversion of alpha-ketoglutarate (α-KG) to 2HG, using a small-molecule inhibitor of the relevant mutant enzyme.
The claim set is method-focused and is built around four main constraints:
- Disease context: AML.
- Target biomarker: mutant IDH1 or mutant IDH2 that produces 2HG.
- Mechanism/functional property: inhibitor blocks the mutant enzyme’s α-KG to 2HG conversion.
- Treatment modality: “administering a therapeutically effective amount” of the inhibitor to the subject.
What is the independent claim (Claim 1) actually doing?
Claim 1 sets the core coverage:
- Subject: a subject having AML.
- Molecular requirement: AML is characterized by mutant IDH1 or IDH2 with the ability to convert α-KG to 2HG.
- Therapy: administering a small molecule inhibitor of the mutant IDH1 or mutant IDH2.
- Functional outcome: the inhibitor acts against the mutant enzyme that drives 2HG production.
This is a classic “method of treatment defined by biomarker + mechanism + administration” structure. It is not limited to a specific chemical identity in the text you provided; it is limited to inhibiting the mutant IDH1/IDH2 that converts α-KG to 2HG.
How do dependent claims narrow the coverage?
Dependent claims 2 to 12 add specificity around (i) binding residues, (ii) whether the leukemia is IDH1- or IDH2-driven, (iii) specific mutation sets, and (iv) detection/diagnostic staging.
Biochemical binding specificity
Claim 2 limits the inhibitor further:
- The inhibitor binds to IDH1R132X or IDH2R172X and inhibits conversion of α-KG to 2HG.
This adds a residue-level binding requirement:
- IDH1R132X (position 132, R132 substituted)
- IDH2R172X (position 172, R172 substituted)
If an accused inhibitor blocks 2HG production without binding at these residues, it is outside this dependent scope, while still potentially within Claim 1 if the inhibitor still targets mutant IDH1/IDH2 function broadly.
Mutation identity and selection lists
The patent then creates two mutation-specific chains:
IDH1 chain
- Claim 3: cancer characterized by an IDH1 mutation
- Claim 4: mutation is IDH1R132X
- Claim 5: mutation is selected from
R132H, R132C, R132S, R132G, R132L, and R132V
IDH2 chain
- Claim 6: cancer characterized by an IDH2 mutation
- Claim 7: mutation is IDH1R172X (note: the claim text you supplied contains “IDH1R172X,” which appears to be a typographical carryover; the logical structure is IDH2R172X residue 172)
- Claim 8: mutation is selected from
R172K, R172M, R172S, R172G, and R172W
From a landscape perspective, the lists are crucial because they track the commonly patented “hotspot” residues of IDH1 and IDH2 oncogenic mutations. Coverage is strongest when a competitor’s compound is positioned for or used on those exact mutation classes.
Diagnostic staging and detection
Claims 9 to 12 add a diagnostic detection step into the method:
- Claim 9: mutant IDH1 or mutant IDH2 is detected in a sample obtained from the subject.
- Claim 10: sample comprises tissue or bodily fluid.
- Claim 11: mutant is detected by sequencing a nucleic acid encoding the relevant mutant amino acid(s) from affected cells.
- Claim 12: sequencing is performed by PCR.
These claims can become a practical enforcement lever in clinical settings where:
- testing is performed to confirm the mutation,
- PCR/sequencing is used to identify the relevant mutant residue,
- the tested result drives administration of the inhibitor.
What is the implied “scope boundary” versus surrounding AML/IDH practice?
Even without compound names, the claims define boundaries that can be tested in claim-chart style:
In-scope characteristics
- The patient has AML (not merely other 2HG-producing IDH-driven malignancies).
- The AML is characterized by mutant IDH1 or mutant IDH2 capable of producing 2HG.
- The administered drug is a small molecule inhibitor of that mutant enzyme.
- In dependent claim pathways, the inhibitor:
- binds at the mutant hotspot residues (IDH1R132X / IDH2R172X), and/or
- is used for specified mutation sets (R132H/C/S/G/L/V or R172K/M/S/G/W), and/or
- is preceded by sample-based detection by sequencing/PCR.
Potential out-of-scope conditions
- If the disease is not AML (for example, MDS or glioma) and there is no AML-specific administration method, the literal “AML characterized” element fails.
- If the inhibitor does not inhibit the mutant enzyme function (for example, inhibits wild-type IDH, or does not block α-KG to 2HG), dependent mechanisms fail and Claim 1 also fails if the mutant’s 2HG conversion is not inhibited in the method’s effect.
- If a compound targets IDH1/2 indirectly without binding the specified residues (Claim 2), it could still fall under Claim 1 if it is still a small-molecule inhibitor of mutant IDH1/2 function, but it falls outside Claim 2.
- If testing is performed without sequencing/PCR (Claims 11-12), those dependent claims are narrower.
How does this claim structure map to the real-world AML IDH1/IDH2 inhibitor market?
US 10,610,125’s claim skeleton aligns tightly with the standard commercialization narratives in IDH-driven AML:
- treat AML patients whose tumors carry IDH1 R132 or IDH2 R172 mutations,
- use a small-molecule inhibitor that blocks 2HG production,
- use molecular diagnostic testing to confirm mutation status before or at time of therapy.
Because the claims are not limited to a specific active ingredient in your excerpt, the patent’s enforceable value depends on whether the asserted compound:
- inhibits mutant IDH1/2 conversion of α-KG to 2HG,
- is used in AML,
- matches the mutation class and, if needed, the residue-binding and diagnostic dependencies.
What is the patent landscape likely to look like around this claim family?
A practical landscape read for US 10,610,125 must consider three overlapping layers that typically control freedom-to-operate (FTO) and patentability in the IDH inhibitor arena:
- Core method-of-treatment patents (AML + mutant IDH1/2 + small-molecule inhibitor blocking 2HG).
- Mutation-specific patents (R132 or R172 hotspot enumerations and related variants).
- Diagnostic companion/biomarker workflow patents (sequencing, PCR assays, tissue/fluids sampling).
In this patent text, Claims 9 to 12 directly target test-and-treat workflows. That means that even if a competitor’s compound is not directly coextensive with Claims 1-8, enforcement can still occur through the diagnostic method when the clinical protocol includes sequencing or PCR to identify the relevant mutant residue and then administers an inhibitor.
What would a claim-by-claim “coverage chart” look like?
Below is a compact mapping of each claim element to the likely litigation questions:
| Claim |
Key limitation(s) |
Most relevant infringement questions |
| 1 |
AML with mutant IDH1 or IDH2 capable of converting α-KG to 2HG; administer small-molecule inhibitor of mutant enzyme |
Is the disease AML? Is the mutation present and producing 2HG? Does the administered small molecule inhibit mutant IDH1/2 function? |
| 2 |
Inhibitor binds IDH1R132X or IDH2R172X and inhibits α-KG to 2HG conversion |
Does binding occur at the hotspot residue (or does the compound’s binding mode avoid these residue interactions)? |
| 3 |
Cancer characterized by IDH1 mutation |
Is it an IDH1-driven AML? |
| 4 |
IDH1 mutation is IDH1R132X |
Is the mutation at residue 132? |
| 5 |
IDH1 mutation in [R132H, R132C, R132S, R132G, R132L, R132V] |
Does the patient/tumor carry one of these listed variants? |
| 6 |
Cancer characterized by IDH2 mutation |
Is it an IDH2-driven AML? |
| 7 |
IDH2 mutation is IDH2R172X (based on logical residue mapping) |
Is the mutation at residue 172? |
| 8 |
IDH2 mutation in [R172K, R172M, R172S, R172G, R172W] |
Does the patient/tumor carry one of these listed variants? |
| 9 |
Mutant IDH1/2 detected in sample from subject |
Is mutation detection performed as part of the claimed method? |
| 10 |
Sample is tissue or bodily fluid |
What sample types are used in the workflow? |
| 11 |
Detection by sequencing nucleic acid encoding mutant amino acid(s) |
Is sequencing part of the method? |
| 12 |
Sequencing by PCR |
Is PCR used as the sequencing method step? |
What does the claim set imply about “design-around” space?
From a freedom-to-operate perspective, the claim design creates multiple potential design-around strategies:
- Compound design-around: if a competitor uses a small molecule that inhibits mutant IDH1/2 2HG production but does not bind the hotspot residues in the claimed manner, Claim 2 may be avoided while Claim 1 remains a risk if mutant inhibition is still satisfied.
- Patient selection design-around: if therapy targets mutations outside the enumerated hotspot variants in Claims 5 and 8, those dependent claims are harder to hit, but Claim 1 still captures “mutant IDH1/2 capable of converting α-KG to 2HG” unless the mutation does not produce 2HG.
- Workflow design-around: if a clinical protocol administers the inhibitor without sequencing/PCR (Claims 9-12), those dependent claims may be avoided even if the treatment itself fits Claims 1-8.
- Disease-type design-around: if the inhibitor is only studied/authorized for other diseases (not AML), then the AML element is a key carve-out. This depends on how the method is asserted in enforcement.
Key enforcement posture signals embedded in these claims
US 10,610,125 builds a litigation-ready combination of:
- a therapeutic method claim (Claim 1),
- a residue-binding dependency (Claim 2),
- mutation-specific dependent claims (Claims 4-5 and 7-8),
- a diagnostic gating step via sequencing and PCR (Claims 9-12).
This structure is common in biologically anchored oncology patents where the commercial route includes:
- mutation testing,
- patient stratification,
- targeted small-molecule administration.
Key Takeaways
- US 10,610,125 claims AML treatment using small-molecule inhibitors that inhibit mutant IDH1/IDH2 function that converts α-KG to 2HG.
- The strongest narrowing hooks are residue-binding to IDH1R132X/IDH2R172X (Claim 2) and the mutation lists for IDH1 (R132H/C/S/G/L/V) and IDH2 (R172K/M/S/G/W) (Claims 5 and 8).
- Claims 9-12 create a test-and-treat workflow pathway by requiring detection of mutant IDH1/2 using sequencing (and specifically PCR as a sequencing method step).
- Practical landscape risk concentrates around products and protocols that combine (i) AML + mutant IDH1/2 + inhibitor administration with (ii) hotspot mutation confirmation by sequencing/PCR.
FAQs
1) Does US 10,610,125 require identification of the specific mutant variant in all cases?
No. Claim 1 requires mutant IDH1 or mutant IDH2 with 2HG-producing function; dependent claims narrow to specific residue sets and enumerated variants (Claims 4-5 and 6-8).
2) Are diagnostic testing steps part of the core claim?
Diagnostic steps appear in dependent claims (Claims 9-12). They are not required by Claim 1 in the excerpt you provided.
3) What is the strongest narrowing feature for the inhibitor in this claim set?
Claim 2 adds that the inhibitor binds to the mutant hotspot residues (IDH1R132X / IDH2R172X) and inhibits α-KG to 2HG conversion.
4) If a competitor’s inhibitor reduces 2HG, is that enough to fall within Claim 1?
Only if it is a small molecule inhibitor of the mutant IDH1 or mutant IDH2 and the method is applied to AML characterized by the relevant mutant that converts α-KG to 2HG.
5) Which dependent claims most directly target how hospitals test patients?
Claims 9-12, particularly Claim 12 requiring PCR sequencing of the nucleic acid encoding the mutant amino acid(s).
References
[1] User-provided excerpt of US 10,610,125 claim text (Claims 1-12).
